PCIA
ABCL icon

Prime Capital Investment Advisors’s AbCellera Biologics ABCL Stock Holding History

Prime Capital Investment Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,028
Closed -$97.1K – 760
2023
Q2 		$97.1K Sell
15,028
-4,404
-23% -$30.1K ﹤0.01% 733
2023
Q1 		$147K Buy
+19,432
New +$176K 0.01% 518

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Prime Capital Investment Advisors's ABCL Position: Q3 2023 in Review

Prime Capital Investment Advisors sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 15,028 shares — an estimated $97.1K sold.

Prime Capital Investment Advisors first reported a position in ABCL in Q1 2023 and held it in 2 quarters. The position peaked at $147K in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Prime Capital Investment Advisors reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 15,028 AbCellera Biologics shares in Q3 2023, an estimated $97.1K.
  • Prime Capital Investment Advisors first reported a position in AbCellera Biologics in Q1 2023 and held it in 2 quarters.
  • Prime Capital Investment Advisors's AbCellera Biologics position peaked at $147K in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Prime Capital Investment Advisors's 13F filing for Q3 2023, filed 9 Nov 2023.